Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons.
Loss of synapses and synaptic damage are the best correlates of cognitive decline identified in patients with Alzheimer's disease (AD), and mitochondrial oxidative damage and synaptic pathology have been identified as early events in the progression of AD. The progressive accumulation of amyloid beta (Aβ) in synapses and synaptic mitochondria are hypothesized to cause synaptic degeneration and cognitive decline in patients with AD. However, the precise mechanistic link between Aβ and mitochondria is not well understood. The purpose of this study was to better understand the effects of Aβ on mitochondrial axonal transport and synaptic alterations in AD. Using mouse hippocampal neurons and Aβ(25-35) peptide, we studied axonal transport of mitochondria, including mitochondrial motility, mitochondrial length and size, mitochondrial index per neurite, and synaptic alterations of the hippocampal neurons. In the PBS-treated neurons, 36.4±4.7% of the observed mitochondria were motile, with 21.0±1.3% moving anterograde and 15.4±3.4% moving retrograde and the average speed of movement was 12.1±1.8μm/min. In contrast, in the Aβ-treated neurons, the number of motile mitochondria were significantly less, at 20.4±2.6% (P<0.032), as were those moving anterograde (10.1±2.6%, P<0.016) relative to PBS-treated neurons, suggesting that the Aβ(25-35) peptide impairs axonal transport of mitochondria in AD neurons. In the Aβ-treated neurons, the average speed of motile mitochondria was also less, at 10.9±1.9μm/min, and mitochondrial length was significantly decreased. Further, synaptic immunoreactivity was also significantly less in the Aβ-treated neurons relative to the PBS-treated neurons, indicating that Aβ affects synaptic viability. These findings suggest that, in neurons affected by AD, Aβ is toxic, impairs mitochondrial movements, reduces mitochondrial length, and causes synaptic degeneration.
Neurogenetics Laboratory, Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, 505 NW 185th Avenue, Beaverton, OR 97006, USA.
Marcus J
MJ
Calkins
P Hemachandra
PH
Reddy
D000544:Alzheimer Disease / Q000378:metabolism* / Q000473:pathology; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000818:Animals; D001370:Axonal Transport; D002478:Cells, Cultured; D006624:Hippocampus / Q000166:cytology; D051379:Mice; D008810:Mice, Inbred C57BL; D008928:Mitochondria / Q000378:metabolism* / Q000473:pathology / Q000648:ultrastructure; D009474:Neurons / Q000378:metabolism / Q000473:pathology*; D010446:Peptide Fragments / Q000378:metabolism*; D013569:Synapses / Q000378:metabolism / Q000473:pathology*
D016229:Amyloid beta-Peptides; D010446:Peptide Fragments; C074636:amyloid beta-protein (25-35)
Neuron. 2008 Dec 10;60(5):748-66
19081372
Brain Res. 1990 May 28;517(1-2):69-75
2376007
Med Hypotheses. 2004;63(1):8-20
15193340
J Neurosci. 2006 Jun 28;26(26):7035-45
16807333
Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5907-12
19321417
Physiol Rev. 2001 Apr;81(2):741-66
11274343
Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19318-23
19050078
Science. 2004 Apr 16;304(5669):448-52
15087549
J Comp Neurol. 1996 Dec 02;376(1):28-44
8946282
Ann Neurol. 1991 Oct;30(4):572-80
1789684
Science. 2010 Oct 8;330(6001):198
20829454
J Neurosci. 2006 Aug 30;26(35):9057-68
16943564
Am J Pathol. 2008 Aug;173(2):470-82
18599615
Biochemistry. 2009 Mar 10;48(9):2045-52
19152501
Nat Med. 2008 Oct;14(10):1097-105
18806802
Neurodegener Dis. 2010;7(1-3):56-9
20160460
Neurobiol Aging. 2005 Oct;26(9):1235-44
16023263
Antioxid Redox Signal. 2007 Oct;9(10):1647-58
17696767
Exp Neurol. 2009 Aug;218(2):286-92
19358844
Nat Rev Neurosci. 2007 Jul;8(7):499-509
17551515
J Neurochem. 1997 Jul;69(1):273-84
9202320
J Alzheimers Dis. 2005 Apr;7(2):103-17; discussion 173-80
15851848
Neurobiol Dis. 2005 Nov;20(2):187-98
16242627
Trends Mol Med. 2008 Feb;14(2):45-53
18218341
Neurobiol Aging. 1990 Jan-Feb;11(1):29-37
2325814
Brain Res Rev. 2011 Jun 24;67(1-2):103-18
21145355
Exp Neurol. 2009 Aug;218(2):308-15
19416677
J Neurosci. 2009 Jul 15;29(28):9090-103
19605646
Hum Mol Genet. 2006 May 1;15(9):1437-49
16551656
J Alzheimers Dis. 2010;20 Suppl 2:S609-31
20463406
FASEB J. 2005 Dec;19(14):2040-1
16210396
Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18670-5
20937894
J Biol Chem. 2006 Apr 28;281(17):11658-68
16517608
Neurobiol Aging. 2003 Dec;24(8):1023-7
14643374
Ann Neurol. 1990 May;27(5):457-64
2360787
J Neurosci. 2010 Mar 24;30(12):4232-40
20335458
J Neurosci Methods. 2004 Jan 15;132(1):101-7
14687679
Hum Mol Genet. 2004 Jun 15;13(12):1225-40
15115763
EMBO J. 2006 Aug 23;25(16):3900-11
16874299
J Neuropathol Exp Neurol. 2001 Aug;60(8):759-67
11487050
Neurology. 1997 Oct;49(4):918-25
9339668
J Neurosci. 2010 Jul 7;30(27):9166-71
20610750
Nature. 2004 Aug 5;430(7000):631-9
15295589
J Neurosci. 2006 Oct 11;26(41):10480-7
17035532
J Cell Sci. 2005 Dec 1;118(Pt 23):5411-9
16306220